E-Learning Center
Join Our Network
OncoFacts

QUICK POLL

Microsatellite Instability (MSI-H) in colon cancer has been associated with which of the following?









 

Celgene Symposium


 

Exploring the Spectrum of Immunomodulatory Therapy in Hematologic Malignancies
A Satellite Symposium at Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies

Friday, October 17, 2008

New York, New York

Waldorf=Astoria

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 1.25 of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for hematologists, oncologists, internists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.

Objectives

After successful completion of this educational activity, attendees should be able to:

  • Discuss emerging therapies in the pipeline for the treatment of lymphoproliferative disorders
  • Assess the emerging role of immunomodulatory agents in the treatment of multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma
  • Interpret recent results with the use of immunomodulatory agents for the treatment of hematologic malignancies
  • Identify future directions with the use of immunomodulatory agents in hematologic malignancies

Asher A. Chanan-Khan, MD
Department of Medicine
School of Medicine & Biomedical Science
Roswell Park Cancer Institute
Buffalo, New York

Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

Paul A. Hamlin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan



Friday, October 17, 2008

11:15 am
Assembly and Lunch

11:35 am
Introductions & opening remarks
Ruben Niesvizky, MD

11:40 am
Exploring the mechanisms of activity of IMiD® compounds
Asher A. Chanan-Khan, MD

11:55 am
Q&A

12:00 am
Evolution in the therapeutic landscape for multiple myeloma
Jeffrey A. Zonder, MD

12:15 pm
Q&A

12:20 pm
Emerging novel therapies for aggressive non-Hodgkin’s lymphomas
Paul A. Hamlin, MD

12:35 pm
Q&A

12:40 pm
Expanding the therapeutic options in CLL
Asher A. Chanan-Khan, MD

12:55 pm
Q&A

1:00 pm
Adjourn

Registration is complimentary to attendees of Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies

Waldorf=Astoria
The Starlight Roof, 18th Floor
New York, New York

Moderator:
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

 

ORGANIZER

Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

PDF Announcement

This meeting is made possible thanks to an unrestricted educational grant from

Wyeth

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.